Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema
Abstract Background To evaluate the additive effect of topical or sub-tenon injection of interferon (IFN)-α 2b in the treatment of refractory diabetic macular edema. Methods In this prospective study patients with center-involved DME who were unresponsive to 3 monthly consecutive IVB injections were...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-022-00424-x |
| _version_ | 1798029915399913472 |
|---|---|
| author | Hooshang Faghihi Bahman Inanloo Arash Mirzaee Kaveh Fadakar Ahmad Mirshahi Nazanin Ebrahimiadib Fariba Ghassemi Fatemeh Bazvand Abdulrahman Amini Masoud Mirghorbani Shahin Faghihi Elias Khalili Pour Hamid Riazi-Esfahani |
| author_facet | Hooshang Faghihi Bahman Inanloo Arash Mirzaee Kaveh Fadakar Ahmad Mirshahi Nazanin Ebrahimiadib Fariba Ghassemi Fatemeh Bazvand Abdulrahman Amini Masoud Mirghorbani Shahin Faghihi Elias Khalili Pour Hamid Riazi-Esfahani |
| author_sort | Hooshang Faghihi |
| collection | DOAJ |
| description | Abstract Background To evaluate the additive effect of topical or sub-tenon injection of interferon (IFN)-α 2b in the treatment of refractory diabetic macular edema. Methods In this prospective study patients with center-involved DME who were unresponsive to 3 monthly consecutive IVB injections were recruited. Patients were divided into three groups: group1, received IFN- α 2b topical drop at a dose of 1mIU/ml four times a day for 3 months. Group 2, received a single sub-tenon injection of 1mIU/ml IFN- α 2b at the enrollment. Group 3 received artificial tears four times a day for 3 months (control group). All groups received three consecutive monthly IVB injections and were evaluated monthly up to 1 month following the last IVB injection. Results In this study, 59 eyes of 35 patients with refractory DME were assessed. The final follow-up showed that although CMT decreased in all groups, only patients in Group 2 had statistically significant lower CMT compared to their baseline values (change in CMT: − 117 ± 213 µm; p-value = 0.025). Comparison of CMT changes between three groups showed no statistically significant difference, although it was higher in group 2 (change in CMT: − 117 ± 213 µm (Group2) vs. − 49 ± 173 (Group 1) vs. − 36 ± 86 (Group 3); p-value = 0.085). Considering eyes with baseline CMT > 400 µm, sub-tenon injection of IFN α2b led to a significant reduction of CMT at the first month and final follow-up visit (CMT change: − 166 ± 210, − 145 ± 231 µm; p-value = 0.018 and 0.035, respectively). In this subgroup, eyes in Group 2 had lower CMT at the first month following treatment in comparison with the control group (CMT: 444 ± 123 µm vs. 544 ± 96 µm, p-value = 0.042). Alterations of CDVA were not statistically significant among groups, although patients in Group 1 had a significant improvement in vision at second and last follow up (CDVA change: − 0.23 ± 0.39, − 0.20 ± 0.43 logMAR; p-value = 0.030 and 0.010, respectively). Conclusions In short term, Sub-tenon injection of IFN might have an additive anatomical effect in eyes with refractory DME. Validation of this observation requires further prospective controlled studies. |
| first_indexed | 2024-04-11T19:31:42Z |
| format | Article |
| id | doaj.art-40ee3753eece462fbd637b89823ca8d4 |
| institution | Directory Open Access Journal |
| issn | 2056-9920 |
| language | English |
| last_indexed | 2024-04-11T19:31:42Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj.art-40ee3753eece462fbd637b89823ca8d42022-12-22T04:06:58ZengBMCInternational Journal of Retina and Vitreous2056-99202022-10-01811910.1186/s40942-022-00424-xEvaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edemaHooshang Faghihi0Bahman Inanloo1Arash Mirzaee2Kaveh Fadakar3Ahmad Mirshahi4Nazanin Ebrahimiadib5Fariba Ghassemi6Fatemeh Bazvand7Abdulrahman Amini8Masoud Mirghorbani9Shahin Faghihi10Elias Khalili Pour11Hamid Riazi-Esfahani12Retina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesRetina Service, Farabi Eye Hospital, Tehran University Of Medical SciencesAbstract Background To evaluate the additive effect of topical or sub-tenon injection of interferon (IFN)-α 2b in the treatment of refractory diabetic macular edema. Methods In this prospective study patients with center-involved DME who were unresponsive to 3 monthly consecutive IVB injections were recruited. Patients were divided into three groups: group1, received IFN- α 2b topical drop at a dose of 1mIU/ml four times a day for 3 months. Group 2, received a single sub-tenon injection of 1mIU/ml IFN- α 2b at the enrollment. Group 3 received artificial tears four times a day for 3 months (control group). All groups received three consecutive monthly IVB injections and were evaluated monthly up to 1 month following the last IVB injection. Results In this study, 59 eyes of 35 patients with refractory DME were assessed. The final follow-up showed that although CMT decreased in all groups, only patients in Group 2 had statistically significant lower CMT compared to their baseline values (change in CMT: − 117 ± 213 µm; p-value = 0.025). Comparison of CMT changes between three groups showed no statistically significant difference, although it was higher in group 2 (change in CMT: − 117 ± 213 µm (Group2) vs. − 49 ± 173 (Group 1) vs. − 36 ± 86 (Group 3); p-value = 0.085). Considering eyes with baseline CMT > 400 µm, sub-tenon injection of IFN α2b led to a significant reduction of CMT at the first month and final follow-up visit (CMT change: − 166 ± 210, − 145 ± 231 µm; p-value = 0.018 and 0.035, respectively). In this subgroup, eyes in Group 2 had lower CMT at the first month following treatment in comparison with the control group (CMT: 444 ± 123 µm vs. 544 ± 96 µm, p-value = 0.042). Alterations of CDVA were not statistically significant among groups, although patients in Group 1 had a significant improvement in vision at second and last follow up (CDVA change: − 0.23 ± 0.39, − 0.20 ± 0.43 logMAR; p-value = 0.030 and 0.010, respectively). Conclusions In short term, Sub-tenon injection of IFN might have an additive anatomical effect in eyes with refractory DME. Validation of this observation requires further prospective controlled studies.https://doi.org/10.1186/s40942-022-00424-xDiabetic retinopathyRefractory diabetic macular edemaInterferon-alphaAnti-vascular endothelial growth factor (Anti-VEGF) |
| spellingShingle | Hooshang Faghihi Bahman Inanloo Arash Mirzaee Kaveh Fadakar Ahmad Mirshahi Nazanin Ebrahimiadib Fariba Ghassemi Fatemeh Bazvand Abdulrahman Amini Masoud Mirghorbani Shahin Faghihi Elias Khalili Pour Hamid Riazi-Esfahani Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema International Journal of Retina and Vitreous Diabetic retinopathy Refractory diabetic macular edema Interferon-alpha Anti-vascular endothelial growth factor (Anti-VEGF) |
| title | Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| title_full | Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| title_fullStr | Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| title_full_unstemmed | Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| title_short | Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| title_sort | evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema |
| topic | Diabetic retinopathy Refractory diabetic macular edema Interferon-alpha Anti-vascular endothelial growth factor (Anti-VEGF) |
| url | https://doi.org/10.1186/s40942-022-00424-x |
| work_keys_str_mv | AT hooshangfaghihi evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT bahmaninanloo evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT arashmirzaee evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT kavehfadakar evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT ahmadmirshahi evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT nazaninebrahimiadib evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT faribaghassemi evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT fatemehbazvand evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT abdulrahmanamini evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT masoudmirghorbani evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT shahinfaghihi evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT eliaskhalilipour evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema AT hamidriaziesfahani evaluationoftheadditiveeffectofinterferona2bwithmonthlyintravitrealinjectionofbevacizumabinrefractorydiabeticmacularedema |